HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
Urvi M ParikhKerri J PenroseAmy L HeapsElias K HalvasB Jay GoetzKelley C GordonRussell HardestyRahil SethiWilliam SchwarzmannDaniel W SzydloMarla J HusnikUma ChandranThesla Palanee PhillipsJared M BaetenJohn W Mellorsnull nullPublished in: Journal of the International AIDS Society (2021)
HIV-1 drug resistance including NNRTI resistance did not differ between the DPV and placebo arms of the MTN-020/ASPIRE study, indicating that drug resistance was not preferentially acquired or selected by the DPV ring and that the preventive benefit of DPV ring outweighs resistance risk.